Business Wire

Reply Announces Collaboration With OpenAI Within the Services Partner Program

30.6.2025 10:00:00 CEST | Business Wire | Press Release

Share

Reply, a global leader in systems integration and consulting, has announced a collaboration with OpenAI becoming an official OpenAI Services Partner. This collaboration places Reply among a distinguished group of companies recognized globally for their expertise in delivering advanced AI solutions that are both scalable and ready for production.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630098393/en/

OpenAI’s Services Partner Program recognizes companies with a proven track record in deploying solutions that unlock real business value. As part of this ecosystem, Reply will continue to support clients with tailored AI solutions and large-scale deployment of AI use cases.

This recognition highlights Reply’s strong technical expertise, reflected in a wide range of successful client implementations and bespoke solutions that leverage AI models to drive transformation in key areas such as employee productivity, customer experience, and software development. Building on this foundation, these solutions span a broad range of business contexts and are organized into three strategic areas: Product Innovation, Conversational Agents & Virtual Assistants, and Software Development Lifecycle.

In the area of Product Innovation, Reply supports its clients in exploring new creative possibilities and reimagining user experiences through AI. Examples include AI-assisted design tools that combine traditional manufacturing processes with machine-generated aesthetics - such as the application of AI models to ceramic design - and the development of personalized travel experiences based on conversational interfaces and contextual data. Reply has also implemented AI-powered platforms that analyze customer behaviors and uncover actionable insights by processing both structured and unstructured data using natural language models.

With regard to Conversational Agents and Virtual Assistants, Reply has delivered intelligent, domain-specific solutions that enhance how users interact with digital services. These include AI-powered customer service assistants for faster and more accurate responses for insurance and customer support, HR assistants that simplify internal navigation for employees, and virtual agents integrated within IoT systems to surface alerts and contextual information through natural language interaction. Each of these assistants has been designed to meet the operational needs and business goals of specific client organizations.

In the field of Software Development Lifecycle, Reply applies AI models to optimize and automate every phase of the SDLC - starting from gathering requirements, through to coding, testing, deployment and release, up to operation and monitoring. AI-powered features such as contextual code review, automated documentation, and design-to-code translation have been integrated into client development pipelines - helping engineering teams increase efficiency, reduce errors, and accelerate time-to-market.

Reply has also applied OpenAI’s technologies in the development of several Prebuilt AI Apps - ready-to-use AI solutions designed to automate specific tasks or sets of related activities within enterprise processes. Built for high reusability with minimal customization, these applications address recurring business needs and help organizations adopt AI more quickly and cost-effectively. Deployed across multiple domains, from procurement and insurance to marketing, HR and compliance. In the insurance sector, AI is used to extract and structure data from invoices and medical reports to support claims management; in marketing, intelligent agents enhance campaign briefs with insights from customer behavior, market trends and competitive analysis.

By combining its expertise in AI, cloud computing, and system integration, Reply enables clients across industries to accelerate innovation using OpenAI’s APIs. This collaboration reinforces Reply’s commitment to help organizations to adopt AI, with a focus on business impact, user experience, and secure implementation.

OpenAI’s Services Partner Program recognizes companies with a proven track record in deploying solutions that unlock real business value. As part of this ecosystem, Reply will continue to support clients with tailored AI solutions and large-scale deployment of AI use cases.

Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specializes in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250630098393/en/

Contacts

Media contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +39 0117711594

Irene Caia
i.caia@reply.com
Tel. +3902545761

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye